ACTI — Active Biotech AB publ Share News
0.000.00%
Last trade - 00:00- SEK367.52m
- SEK314.32m
Brief: Active Biotech Q1 Loss After Tax At SEK 8.4 Million
Brief: Active Biotech Q4 Operating Loss SEK 9.1 Million
Brief: Active Biotech Announces Outcome Of Rights Issue
Brief: Active Biotech: Patent To Be Granted In U.S.
Brief: Active Biotech Q3 Operating Loss Of SEK 6.0 Million
Brief: Active Biotech Announces Rights Issue Of About SEK 70 Mln
Brief: Active Biotech To Present Positive LION Studies Results In Orlando
Brief: Active Biotech Reports Q2 Loss After Tax Of SEK 11.2 Mln
Brief: Active Biotech Q2 Operating Loss Of SEK 11.3 MLN
Brief: Active Biotech Releases Tasquinimod Study Results For RRMM
Brief: Active Biotech Study Confirms Tasquinimod Has Anti-Myeloma Activity
Brief: Active Biotech Says Patent For Tasquinimod In Myelofibrosis Granted In Europe
Brief: Active Biotech Q1 EBIT at SEK -11.2 Million
Brief: Active Biotech Reports Positive Top-Line Results From LION Study
Brief: Active Biotech Q4 Operating Loss At SEK 10.3 Mln
Brief: Active Biotech's Patent For Laquinimod In Eye Disorders Granted In U.S.
Brief: Active Biotech Raises SEK 43.4 Mln In Oversubscribed Rights Issue
Brief: Active Biotech's Patent For Laquinimod In Eye Disorders To Be Granted In US
Brief: EPO Grants Active Biotech's Patent Application For Eye Drop Formulation Of Laquinimod